Conditions

This post was originally published on this site In a video posted on Healio’s Hematology-Oncology page, Dr. Ola Landgren, chief of the myeloma service at Memorial Sloan Kettering Cancer Center in New York City, speaks about new treatments and ongoing discoveries in the field of multiple myeloma. A lot is taking place, quickly, according to Landgren. “I…

This post was originally published on this site The Multiple Myeloma Research Foundation (MMRF) and the University of Michigan have partnered to provide multiple myeloma patients and their doctors access to personal genomic information which can help guide treatments based on genomic alterations. Over the course of the two-year Molecular Profiling Initiative (MPI), the two institutions…

This post was originally published on this site Juno Therapeutics and privately held biotech Eureka Therapeutics have entered into an immunotherapy development partnership with Memorial Sloan Kettering Cancer Center (MSK) of New York City. The exclusive license agreement is for joint development of a novel fully-human binding domain targeting B-cell maturation antigen (BCMA), and binding domains against two…

This post was originally published on this site The rate of obesity increased faster among cancer survivors than the general population in the 14 years between 1997 and 2014, according to a study published in the Journal of Clinical Oncology. “We knew that obesity rates have been increasing in the general population, but we did…

This post was originally published on this site Patients being treated with a combination 5-alpha reductase inhibitor (5ARIs) and an alpha blocker may switch to 5ARIs alone with no worsening of lower urinary tract symptoms (LUTS), a new study says. But in overweight patients, the withdrawal must be carefully monitored. These findings, in the study “Effects of…

This post was originally published on this site Naftopidil, a medication used to treat benign prostatic hyperplasia (BPH) outside the United States, lowers blood pressure in BPH men with hypertension while having no effect on those with normal blood pressure, a Korean study found. The drug, an alpha-blocker, also improved prostate symptoms and quality of…

This post was originally published on this site Fexapotide triflutate improves the sexual functioning of men with an enlarged prostate, according to combined results of four Phase 3 clinical trials. The therapy’s developer, Nymox Pharmaceutical, had previously reported that Fexapotide caused no sexual or other side effects, but improved sexual function is a new and important finding.…

This post was originally published on this site One in three women with metastatic triple-negative breast cancer — all of whom had received at least two prior treatments — saw their tumors shrink after receiving Immunomedics‘ investigational treatment sacituzumab govitecan as part of a Phase 1/2 trial, a new study shows. In addition to increasing response rates, the treatment…

This post was originally published on this site Metastatic breast cancer patients in the European Union will have the possibility of being treated with a biosimilar of Avastin (bevacizumab), following the approval of Pfizer’s Zirabev (bevacizumab) as a more affordable treatment with similar efficacy to the original. Zirabev is the second biosimilar to Avastin approved by the…

This post was originally published on this site Very few cancer cells within a triple negative breast tumor (TNBC) are able to spread and grow in distant organs (metastasize), although most are able to shed from the original tumor and be resistant to therapy, a new technique called cellular barcoding has shown. Combining this advanced tool with…

This post was originally published on this site   The hardest part of cancer? That’s a loaded question, but telling my kid about it ranks up there at the top of that list. Lauren had just turned 10 when my husband and I found a lump in my breast. A few days later, an oncologist…

This post was originally published on this site A new imaging agent that successfully measures changes in progesterone receptor (PR) levels may be used to determine if a breast cancer patient will respond to hormone therapies targeting the estrogen receptor (ER), a study suggests. The study, “Sensitivity and Isoform Specificity of 18F-Fluorofuranylnorprogesterone for Measuring Progesterone Receptor…